Literature DB >> 832074

Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly.

J S MacKenzie.   

Abstract

Antibody responses to subunit influenza vaccine prepared against A2/England/42/72 (h3n2) were studied in 69 volunteers aged 60 and over and 231 aged 59 and below over 12 months in 1973 and 1974. After two doses of vaccine seroconversion frequencies and geometric mean haemagglutination-inhibition (HI) titres were higher in the elderly, but no differences were observed between the two groups in the length of their responses. Sixteen (23%) of the elderly volunteers seroconverted only after receiving a second dose of vaccine or seroconverted twice after receiving both doses of vaccine. It was considered justifiable, therefore, to recommend the continuation of a two-dose schedule for patients in a high-risk category. Within 30 weeks of vaccination 87 (29%) volunteers had considerably reduced HI titres (less than 48), which might indicate potential susceptibility to influenza during an epidemic, and the number had risen to 132 (44%) by 50 weeks. It was suggested that high-risk patients should receive annnual vaccination two to four months before the possible epidemic period.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832074      PMCID: PMC1604447          DOI: 10.1136/bmj.1.6055.200

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  Observations on excess mortality associated with epidemic influenza.

Authors:  T C EICKHOFF; I L SHERMAN; R E SERFLING
Journal:  JAMA       Date:  1961-06-03       Impact factor: 56.272

2.  The risk of acute respiratory infections in two groups of young adults in Colombia, South America. A prospective seroepidemiologic study.

Authors:  A S Evans; C Jeffrey; J C Niederman
Journal:  Am J Epidemiol       Date:  1971-06       Impact factor: 4.897

3.  Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity.

Authors:  D Hobson; F A Baker; R L Curry
Journal:  Lancet       Date:  1973-07-21       Impact factor: 79.321

4.  Effect of two doses of influenza vaccine in stimulating antibody in volunteers.

Authors:  C H Howells; A D Evans; C Vesselinova-Jenkins
Journal:  Lancet       Date:  1973-06-23       Impact factor: 79.321

5.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

6.  Age-related response to 1000 CCA unit zonally purified, inactivated influenza vaccines in volunteers in the U.S.A.

Authors:  W M Marine; J E Thomas
Journal:  Postgrad Med J       Date:  1973-03       Impact factor: 2.401

7.  Comparative trials of live attenuated and detergent split influenza virus vaccines.

Authors:  J S Mackenzie; I Mackenzie; J Lloyd; V Dent
Journal:  J Hyg (Lond)       Date:  1975-12
  7 in total
  13 in total

1.  Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests.

Authors:  A M Iorio; T Zei; M Neri; L Campitelli; M R Castrucci; I Donatelli
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

2.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy.

Authors:  W Lo; E Whimbey; L Elting; R Couch; F Cabanillas; G Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

Review 4.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study.

Authors:  Shuo Feng; Susan S Chiu; Eunice L Y Chan; Mike Y W Kwan; Joshua S C Wong; Chi-Wai Leung; Yiu Chung Lau; Sheena G Sullivan; J S Malik Peiris; Benjamin J Cowling
Journal:  Lancet Respir Med       Date:  2018-11-12       Impact factor: 30.700

6.  Comparison of one- and two-dose regimens of influenza vaccine for elderly men.

Authors:  M Levine; B L Beattie; D M McLean
Journal:  CMAJ       Date:  1987-10-15       Impact factor: 8.262

7.  Influenza in a geriatric unit.

Authors:  H T Gowda
Journal:  Postgrad Med J       Date:  1979-03       Impact factor: 2.401

8.  Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

9.  The effect of ABO blood groups on the incidence of epidemic influenza and on the response to live attenuated and detergent split influenza virus vaccines.

Authors:  J S Mackenzie; P J Fimmel
Journal:  J Hyg (Lond)       Date:  1978-02

10.  Influenza vaccination in elderly residents in nursing homes: immune response to trivalent and monovalent inactivated influenza virus vaccine in the season 1986-87.

Authors:  G Mancini; G Arangio-Ruiz; B Bianchi; L Diana; T Macchia; I Donatelli; M R Castrucci; L Campitelli; A Ruggieri
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.